The European Patent Office grants patent for tasquinimod for treatment of multiple myeloma

09.01.17 13:05
The European Patent Office grants patent for tasquinimod for treatment of multiple myeloma

Lund January 9, 2017 - Active Biotech AB (Nasdag Stockholm: ACTI)  announces today that the European Patent Office has decided to grant Active Biotech's patent application covering tasquinimod for use in the treatment of multiple myeloma. The patent will be granted as European Patent No. 3041472 on February 1, 2017 and has a duration lasting until 2035.  

For further information, please contact:

  Tomas Leanderson, President & CEO

  Tel: +46 46 19 20 95


  Hans Kolam, CFO

  Tel: +46 46 19 20 44


Active Biotech AB

( 556223-9227)

Box 724, 220 07 Lund

Tel: +46 46 19 20 00


About tasquinimod

Tasquinimod is an immunomodulatory, anti-metastatic and anti-angiogenic compound that affects the tumor's ability to grow and spread. The development of tasquinimod has previously been focused on the treatment of prostate cancer with clinical proof of concept and a good safety profile shown in Phase 2 and 3 studies.  Tasquinimod's mechanism of action is broadly applicable as anti-tumor treatment and very good results have been achieved in models for multiple myeloma, a blood cancer with a high medical need. Active Biotech is seeking a partner for the continued development of tasquinimod in multiple myeloma.

Active Biotech AB (publ) (Nasdag Stockholm: ACTI) is a biotechnology company with focus on neurodegenerative/inflammatory diseases and cancer. Laquinimod, an orally administered small molecule with unique immunomodulatory properties, is in pivotal Phase 3 development for the treatment of relapsing remitting multiple sclerosis. Also, laquinimod is in Phase 2 development for the treatment of primary progressive multiple sclerosis and Huntington's disease. Furthermore, commercial activities are conducted for the tasquinimod, paquinimod and SILC projects. Please visit for more information.

This information is information that Active Biotech AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 13.00 pm CET on January 9, 2017.

The European Patent Office grants patent for tasquinimod for MM

This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Active Biotech via Globenewswire


Breaking News

Kurs- und weitere Informationen zum Thema:

Active Biotech

Aktuelle Diskussionen zum Thema:

Active Biotech - Rebound alter ... (25.01.18)

Aktuelle Nachrichten zum Unternehmen:

Active Biotech AB bricht nach en. (01.08.11)
Active Biotech bricht nach enttäus. (01.08.11)
Evotec und Active Biotech vereinb. (06.06.11)
Evotec und Active Biotech unterze. (11.03.10)

Alle Nachrichten zum Unternehmen

Aktuelle Analysen zu den Unternehmen:

Active Biotech
Weitere Meldungen
10.01 Ad hoc: HumanOptics AG e.
10.01 Talvivaara Mining Company .
10.01 The court of arbitration dism.
10.01 L'ORÉAL: News Release: "L.
10.01 EQS-Adhoc: ACRON HELVE.
09.01 EVS Broadcast Equipment: .
09.01 Agfa-Gevaert : Classic Fund.
09.01 EQS-Adhoc: LifeWatch AG:.
09.01 Ad hoc: MAX 21 AG führt.
09.01 Ad hoc: Accentro Real Esta.
09.01 Ad hoc: PANTALEON Ente.
09.01 Ad hoc: Bijou Brigitte modis.
09.01 Ad hoc: PNE WIND AG ve.
09.01 Ad hoc: Neschen AG: Verä.
09.01 Outotec and Outokumpu sett.
09.01 The European Patent Office.
09.01 Ahold Delhaize commences .
09.01 Cancellation of Extraordinary.
09.01 TGS Q4 2016 Update and .
09.01 SOITEC : Launch of the rev.
09.01 DBV Technologies Announce.
09.01 Addex ADX71441 Demonstr.
09.01 Takeda notifies 4.48% share.
09.01 DNO Makes Cretaceous Oil .
08.01 Ad hoc: Die Geschäftsführu.
07.01 Ad hoc: Fresenius Medical C.
06.01 Ad hoc: Pütz Vermögensver.
06.01 Ad hoc: Pelikan Aktiengesel.
06.01 Ad hoc: AG: .

Welche Social Networks nutzen Sie meistens?
Linked in

Stimmen: 37254 , Ergebnis

Status: nicht eingeloggt

Registrieren | Passwort vergessen?
Im Bereich Nachrichten:
Wirecard: Die Unterstützung hält!
Experte: Stefan Hofmann, STOCK-WORLD
DOW DAX schliesst das ...
Thomas Heydrich, (20.06.18)
Experte: Thomas Heydrich,
DAX weiter impulslos ...
CMC Markets, (20.06.18)
Experte: CMC Markets,
Devin Sage TXA Trading ...
Devin Sage, (20.06.18)
Experte: Devin Sage,
Anleger wagen sich ein ...
Cornelia Frey, Börse Stuttgart AG (20.06.18)
Experte: Cornelia Frey, Börse Stuttgart AG
Kupfer: Wie geht es jetzt ...
Jürgen Sterzbach, (20.06.18)
Experte: Jürgen Sterzbach,
Klingelnberg starten bei ...
Volker Gelfarth, (20.06.18)
Experte: Volker Gelfarth,
„Buy the Dips“ Verhalten der ...
Silvio Graß, Formationstrader (20.06.18)
Experte: Silvio Graß, Formationstrader
S&P500 zieht vorbörslich ...
Christian Zoller, (20.06.18)
Experte: Christian Zoller,
SJB FondsEcho. ...
Gerd Bennewirtz, SJB FondsSkyline (20.06.18)
Experte: Gerd Bennewirtz, SJB FondsSkyline
EURUSD-Analyse: Trump ...
Admiral Markets, (20.06.18)
Experte: Admiral Markets,
Börsengeflüster: #PEACH ...
VW – Analyst senkt den ...
Feingold-Research, (20.06.18)
Experte: Feingold-Research,
Niquet's World
Neues vom Portal
Aktienmarkt bietet zahlreiche Möglichkeiten fürs Geld verdienen
Letzte Börsen-Meldung
Letzte Börsen-Analyse
Top-Klicks News
Top-Klicks Analysen